All Releases
 |
Anthera Pharmaceuticals Announces Personnel Changes
Jun 12, 2013
|
11.5 KB |
|
| |
HAYWARD, Calif., June 12, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced the appointment of May Liu as its Senior Vice President, Finance and Administration. In this position, Ms. Liu will oversee the finance, investor relations and general administration functions of Anthera in addition to her role as Principal ...
|
|
Anthera Pharmaceuticals to Present at Annual Jefferies Healthcare Conference
May 31, 2013
|
10.9 KB |
|
| |
HAYWARD, Calif., May 31, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, announced today that Paul F. Truex, President and Chief Executive Officer, and Dr. Colin Hislop, Senior Vice President and Chief Medical Officer, wil...
|
|
Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results
May 13, 2013
|
17.1 KB |
|
| |
HAYWARD, Calif., May 13, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and business highlights for the quarter ended March 31st, 2013.
First Quarter 2013 Financial Results:
Loss from operations, which included a non-recurring and non-cash charge of approximately $1.5 million in ...
|
|
Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study
May 7, 2013
|
14.5 KB |
|
| |
HAYWARD, Calif., May 7, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, today announced that additional data from its Phase 2b PEARL-SC study will be presented in two lecture sessions at the European League Against Rheumat...
|
|
Anthera Announces First Quarter 2013 Financial Report and Conference Call
May 3, 2013
|
9.5 KB |
|
| |
HAYWARD, Calif., May 3, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, will release its first quarter 2013 financial report after market close on Monday, May 13th. Anthera will host a Corporate Update conference call on M...
|
|
Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
Apr 5, 2013
|
13.4 KB |
|
| |
HAYWARD, Calif., April 5, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced that it has secured a new $20.0 million debt financing facility through a syndicate led by MidCap Financial SBIC, LP ("MidCap Financial"). A...
|
|
Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
Mar 27, 2013
|
13.0 KB |
|
| |
HAYWARD, Calif., March 27, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced it has initiated the CHABLIS-SC1 Phase 3 study of blisibimod, a novel inhibitor of B-Cell Activating Factor (BAFF)...
|
|
Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Mar 26, 2013
|
15.0 KB |
|
| |
HAYWARD, Calif., March 26, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and business highlights for the quarter and fiscal year ended December 31, 2012.
Fourth Quarter and Fiscal Year 2012 Financial Results:
Total operating expenses for the fourth quarter ended December 31, 201...
|
|
Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
Mar 22, 2013
|
11.3 KB |
|
| |
HAYWARD, Calif., March 22, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced its abstract entitled "Blisibimod, an Emerging Subcutaneous Biologic Therapy for Patients with Active, Moderate-to...
|
|
Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
Feb 7, 2013
|
9.0 KB |
|
| |
HAYWARD, Calif., Feb. 7, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced Paul F. Truex, Anthera's President and Chief Executive Officer, will present at the 2013 Leerink Global Healthcare Co...
|
|
Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
Feb 5, 2013
|
10.5 KB |
|
| |
HAYWARD, Calif., Feb. 5, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced that Senior Vice President of Product Development Georgina Kilfoil has notified the company she will leave the company effective February 15, 2013 to pursue other opportunities.
"The Board and management of Anthera would like to thank ...
|
|
Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
Jan 30, 2013
|
11.6 KB |
|
| |
HAYWARD, Calif., Jan. 30, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced that it has completed the previously announced underwritten public offering of 60,606,061 shares of its common stock, offered at a price of $0.66 per share. In addition, Anthera has granted the underwriters a 30-day option to purchase up to ...
|
|
Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Jan 25, 2013
|
11.8 KB |
|
| |
HAYWARD, Calif., Jan. 25, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced the pricing of an underwritten public offering of 60,606,061 shares of its common stock, offered at a price of $0.66 per share. The Company estimates that the gross proceeds from the offering, before deducting underwriting discounts and comm...
|
|
Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
Jan 24, 2013
|
11.6 KB |
|
| |
HAYWARD, Calif., Jan. 24, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the p...
|
|
Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
Nov 28, 2012
|
12.1 KB |
|
| |
HAYWARD, Calif., Nov. 28, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced additional data from its Phase 2b PEARL-SC study was presented in a poster at the 2012 Asian Lupus Summit. The post...
|
|
Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
Nov 20, 2012
|
8.9 KB |
|
| |
HAYWARD, Calif., Nov. 20, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced that Paul F. Truex, Anthera's President and Chief Executive Officer, will present at the Piper Jaffray Health Care ...
|
|
Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
Nov 13, 2012
|
14.2 KB |
|
| |
HAYWARD, Calif., Nov. 13, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced additional data from its Phase 2b PEARL-SC study presented in a late breaking poster at the 2012 Annual Scientific ...
|
|
Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
Nov 1, 2012
|
12.0 KB |
|
| |
HAYWARD, Calif., Nov. 1, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced that an abstract of the results from the Phase 2b PEARL-SC clinical study examining the treatment effect of blisibim...
|
|
Anthera Pharmaceuticals Reports 2012 Third Quarter Financial Results And Provides Clinical Progress Update
Oct 24, 2012
|
18.9 KB |
|
| |
HAYWARD, Calif., Oct. 24, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and business highlights for the quarter ended September 30, 2012.
Financial Results and Corporate Update:
Total operating expenses for the third quarter ended September 30, 2012 were $12.0 million, as compar...
|
|
Anthera Announces Third Quarter 2012 Financial Report and Conference Call
Oct 18, 2012
|
9.3 KB |
|
| |
HAYWARD, Calif., Oct. 18, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, will release its third quarter 2012 financial report after market close on Wednesday, October 24, 2012. Anthera will host a confere...
|
|
|
